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We read with interest the paper by Dr Inciardi et al.1 showing higher mortality and 
thromboembolic events in cardiac patients with COVID-19. Higher prevalence of heart 
failure and hypertension in this cohort, conditions associated with reduced angiotensin 
converting enzyme 2 (ACE2) levels, lead us to propose that ACE2 may mediate some of the 
prothrombotic effects of the SARS-CoV-2 virus.  
Thrombotic complications are prevalent in COVID-19, contributing to mortality and 
morbidity.2 Following the recognition that SARS-CoV-2 enters the host cell by binding to 
ACE2, there has been controversy regarding use of angiotensin converting enzyme inhibitors 
(ACE-i) in infected individuals, since ACE-i upregulate ACE2 and theoretically may increase 
infectability of the host. Tissue distribution of ACE2 includes lung alveolar epithelial cells, 
enterocytes, arterial and venous endothelial cells, arterial smooth muscle and nasal and oral 
epithelium, mirroring the clinical manifestations of COVID-19 in ARDS, diarrhoea, 
thrombosis, anosmia and ageusia, respectively.  
ACE-i use has been associated with increased ACE2 expression and in animals, ACE-i 
infusion increased the number of ACE2 receptors in the cardiopulmonary circulation. 
Increase in pulmonary ACE2 receptors for SARS-CoV-2 to bind may increase the risk of 
severe disease manifestation. 
However, ACE-i use is protective against COVID-19 mortality,3 which initially appears 
counter-intuitive. Following the binding of the virus, expression and enzymatic activity of 
ACE2 are significantly reduced, likely due to enhanced shedding, whereby the extracellular 
component of ACE2 is cleaved, with release of the resultant soluble protein, reducing surface 
expression and activity. This reduction in ACE2 expression may contribute to the virulence 
of SARS-CoV-2. Patient characteristics associated with severe disease, such as hypertension, 
diabetes and obesity have been linked to lower plasma ACE2 levels, and may explain why 
ACE-i-treated patients appear protected. The location of the ACE2 gene on the X-
chromosome, and oestrogen-dependent activation of ACE2, may account for the better 
prognosis in women with COVID-19.  
Reduction in ACE2 activity increases vascular permeability, leading to tissue factor (TF) 
expression in subendothelial cells as well as in leukocytes and platelets, which can trigger 
coagulation, thrombosis and disseminated intravascular coagulation.3 ACE2 may exert 
antithrombotic effects, through a number of mechanisms, the most important being the renin-
angiotensin pathway, in which angiotensin I is converted by ACE to angiotensin II (Ang II), 
which is then broken down by ACE2 to Ang(1–7). Reduction in ACE2 leads to an increase in 
Ang II, which stimulates plasminogen activator inhibitor 1 (PAI-1) expression in a variety of 
cells, including smooth muscle cells, endothelial cells and adipocytes.4 PAI-1 is the major 
inhibitor of the plasma fibrinolytic cascade and ACE-i reduced PAI-1 levels in experimental 
and clinical studies.4 Ang II also appears to sensitize platelets to the effects of classical 
platelet agonists.4 Patients with COVID-19 appear to have elevated levels of plasma Ang II, 
which in turn correlate with viral load and degree of lung injury.5 
In conclusion, reduction of ACE2 due to SARS-CoV-2 infection and the resultant 
endothelial dysfunction, release of TF and impaired fibrinolysis could explain the thrombotic 















Take Home Figure 
Thrombotic complications in patients with COVID-19 related to angiotensin converting enzyme 2 (ACE2) 
activity. SARS-CoV-2 binding to ACE2 receptors induce enhanced shredding of ACE2, with resultant (1) 
increase vascular permeability, subsequent tissue factor exposure and activation of extrinsic coagulation 
pathway and (2) increase in angiotensin II levels, subsequent increase in plasminogen activator inhibitor 1 (PAI-
1) levels and reduction of fibrinolytic activity.   
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